You can now read 10 articles in a month for free on BostonGlobe.com. Read as much as you want anywhere and anytime for just 99¢.

The Boston Globe

Business

Genzyme’s new MS therapy OK’d by European officials

European regulators Tuesday put their stamp of approval on Genzyme’s multiple sclerosis drug Lemtrada, giving the Cambridge biotechnology company a second MS treatment for the overseas market only weeks after its first won approval there.

The move vindicated French drug maker Sanofi SA’s decision to pay $20.1 billion for Genzyme in 2011, a deal that hinged on the potential of Lemtrada, then an experimental therapy.

Loading comments...

You have reached the limit of 10 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week